Literature DB >> 24055497

Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Christie D Fowler1, Paul J Kenny.   

Abstract

Nicotine stimulates brain reward circuitries, most prominently the mesocorticolimbic dopamine system, and this action plays a critical in establishing and maintaining the tobacco smoking habit. Compounds that attenuate nicotine reward are considered promising therapeutic candidates for tobacco dependence, but many of these agents have other actions that limit their potential utility. Nicotine is also highly noxious, particularly at higher doses, and aversive reactions to nicotine after initial exposure can decrease the likelihood of developing a tobacco habit in many first time smokers. Nevertheless, relatively little is known about the mechanisms of nicotine aversion. The purpose of this review is to present recent new insights into the neurobiological mechanisms that regulate avoidance of nicotine. First, the role of the mesocorticolimbic system, so often associated with nicotine reward, in regulating nicotine aversion is highlighted. Second, genetic variation that modifies noxious responses to nicotine and thereby influences vulnerability to tobacco dependence, in particular variation in the CHRNA5-CHRNA3-CHRNB4 nicotinic acetylcholine receptor (nAChR) subunit gene cluster, will be discussed. Third, the role of the habenular complex in nicotine aversion, primarily medial habenular projections to the interpeduncular nucleus (IPN) but also lateral habenular projections to rostromedial tegmental nucleus (RMTg) and ventral tegmental area (VTA) are reviewed. Forth, brain circuits that are enriched in nAChRs, but whose role in nicotine avoidance has not yet been assessed, will be identified. Finally, the feasibility of developing novel therapeutic agents for tobacco dependence that act not by blocking nicotine reward but by enhancing nicotine avoidance will be considered. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aversion; Dopamine; Drug discovery; Habenula; Interpeduncular nucleus; Nicotine; Reward; Rostromedial tegmental nucleus; Tobacco

Mesh:

Substances:

Year:  2013        PMID: 24055497      PMCID: PMC3858456          DOI: 10.1016/j.neuropharm.2013.09.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  190 in total

1.  Alpha 5, alpha 3, and non-alpha 3. Three clustered avian genes encoding neuronal nicotinic acetylcholine receptor-related subunits.

Authors:  S Couturier; L Erkman; S Valera; D Rungger; S Bertrand; J Boulter; M Ballivet; D Bertrand
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

2.  Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.

Authors:  F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2008-04-02       Impact factor: 6.875

3.  Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.

Authors:  Kerri A Schoedel; Edward M Sellers; Roberta Palmour; Rachel F Tyndale
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

4.  Targeted in vivo expression of nicotinic acetylcholine receptors in mouse brain using lentiviral expression vectors.

Authors:  B E Molles; U Maskos; S Pons; M Besson; P Guiard; J-P Guilloux; A Evrard; A Cormier; M Mameli-Engvall; I Cloëz-Tayarani; H Nakatani; N Dufour; A-P Bemelmans; J Mallet; P Cazala; A M Gardier; V David; P Faure; S Granon; J-P Changeux
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

5.  Control of behavior by intravenous nicotine injections in laboratory animals.

Authors:  S R Goldberg; R D Spealman; M E Risner; J E Henningfield
Journal:  Pharmacol Biochem Behav       Date:  1983-12       Impact factor: 3.533

6.  Allosteric effects of diprobutine on acetylcholine receptors.

Authors:  P Chemouilli; T Heidmann; J P Changeux; A Bachy; M Morre
Journal:  Eur J Pharmacol       Date:  1985-11-05       Impact factor: 4.432

7.  Nicotine maintains robust self-administration in rats on a limited-access schedule.

Authors:  W A Corrigall; K M Coen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Authors:  Noritaka Ariyoshi; Masami Miyamoto; Yuri Umetsu; Hideo Kunitoh; Hirotoshi Dosaka-Akita; Yu-Ichi Sawamura; Jun Yokota; Nobuo Nemoto; Kunio Sato; Tetsuya Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

9.  Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice.

Authors:  Ramiro Salas; Renea Sturm; Jim Boulter; Mariella De Biasi
Journal:  J Neurosci       Date:  2009-03-11       Impact factor: 6.167

10.  alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors.

Authors:  V Gerzanich; F Wang; A Kuryatov; J Lindstrom
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

View more
  71 in total

1.  How Intravenous Nicotine Administration in Smokers Can Inform Tobacco Regulatory Science.

Authors:  Kevin P Jensen; Elise E DeVito; Mehmet Sofuoglu
Journal:  Tob Regul Sci       Date:  2016-10-01

2.  Chrna5-Expressing Neurons in the Interpeduncular Nucleus Mediate Aversion Primed by Prior Stimulation or Nicotine Exposure.

Authors:  Glenn Morton; Nailyam Nasirova; Daniel W Sparks; Matthew Brodsky; Sanghavy Sivakumaran; Evelyn K Lambe; Eric E Turner
Journal:  J Neurosci       Date:  2018-06-28       Impact factor: 6.167

3.  Genetics: No more addictive personality.

Authors:  Maia Szalavitz
Journal:  Nature       Date:  2015-06-25       Impact factor: 49.962

Review 4.  Inhalation of Alcohol Vapor: Measurement and Implications.

Authors:  Robert Ross MacLean; Gerald W Valentine; Peter I Jatlow; Mehmet Sofuoglu
Journal:  Alcohol Clin Exp Res       Date:  2017-01-05       Impact factor: 3.455

5.  Serotonin stimulates lateral habenula via activation of the post-synaptic serotonin 2/3 receptors and transient receptor potential channels.

Authors:  Wanhong Zuo; Yong Zhang; Guiqin Xie; Danielle Gregor; Alex Bekker; Jiang-Hong Ye
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

6.  Crucial role of nicotinic α5 subunit variants for Ca2+ fluxes in ventral midbrain neurons.

Authors:  Miriam Sciaccaluga; Claudia Moriconi; Katiuscia Martinello; Myriam Catalano; Isabel Bermudez; Jerry A Stitzel; Uwe Maskos; Sergio Fucile
Journal:  FASEB J       Date:  2015-04-24       Impact factor: 5.191

7.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

8.  Effects of acute and chronic nicotine on catecholamine neurons of the nucleus of the solitary tract.

Authors:  Stephen J Page; Mingyan Zhu; Suzanne M Appleyard
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-10-24       Impact factor: 3.619

9.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

10.  Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats.

Authors:  M G LeSage; M Staley; P Muelken; J R Smethells; I Stepanov; R I Vogel; P R Pentel; A C Harris
Journal:  Drug Alcohol Depend       Date:  2016-09-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.